CN112424233A - 包含颗粒蛋白前体的融合蛋白 - Google Patents
包含颗粒蛋白前体的融合蛋白 Download PDFInfo
- Publication number
- CN112424233A CN112424233A CN201980039158.0A CN201980039158A CN112424233A CN 112424233 A CN112424233 A CN 112424233A CN 201980039158 A CN201980039158 A CN 201980039158A CN 112424233 A CN112424233 A CN 112424233A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- protein
- seq
- sequence
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686579P | 2018-06-18 | 2018-06-18 | |
| US62/686,579 | 2018-06-18 | ||
| US201862746338P | 2018-10-16 | 2018-10-16 | |
| US62/746,338 | 2018-10-16 | ||
| PCT/US2019/037695 WO2019246071A1 (en) | 2018-06-18 | 2019-06-18 | Fusion proteins comprising progranulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112424233A true CN112424233A (zh) | 2021-02-26 |
Family
ID=67138158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980039158.0A Pending CN112424233A (zh) | 2018-06-18 | 2019-06-18 | 包含颗粒蛋白前体的融合蛋白 |
Country Status (17)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| AU2016270587B2 (en) * | 2015-05-29 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| SMT202300110T1 (it) | 2018-07-13 | 2023-05-12 | Alector Llc | Anticorpi anti-sortilina e relativi metodi di uso |
| CA3109763A1 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| US20210396772A1 (en) * | 2018-10-16 | 2021-12-23 | Denali Therapeutics Inc. | Methods for treating and monitoring progranulin-associated disorders |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| BR112022012230A2 (pt) * | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CN116133684B (zh) * | 2020-05-27 | 2025-07-18 | 阿里亚利斯治疗公司 | 抗人nr1抗体衍生物 |
| US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| KR102666958B1 (ko) * | 2020-09-18 | 2024-05-23 | 한양대학교 산학협력단 | PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물 |
| EP4215607A4 (en) * | 2020-09-18 | 2024-11-06 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Ptpsigma-fc fusion protein and pharmaceutical composition comprising same |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| EP4229419A2 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| AR128003A1 (es) * | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
| WO2023198661A1 (en) * | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
| CN119213030A (zh) * | 2022-05-16 | 2024-12-27 | 戴纳立制药公司 | 转铁蛋白受体结合结构域和包含其的蛋白 |
| JP2024037109A (ja) * | 2022-09-06 | 2024-03-18 | 国立大学法人九州大学 | 分析容器、前処理方法、代謝物解析方法、タンパク質解析方法、及び質量分析方法 |
| EP4630030A2 (en) * | 2022-12-06 | 2025-10-15 | ProteinQure Inc. | Targeting sortilin |
| EP4731669A2 (en) * | 2023-06-21 | 2026-04-29 | Eli Lilly and Company | Compounds for the delivery of granulin across the blood brain barrier |
| WO2025051953A1 (en) * | 2023-09-07 | 2025-03-13 | Novo Nordisk A/S | Sortilin-1 binders, constructs and uses thereof |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2025166077A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| EP4755905A1 (en) | 2024-12-05 | 2026-06-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Truncated progranulin protein and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022175A1 (en) * | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| WO2016207240A1 (en) * | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| US20170210808A1 (en) * | 2015-04-07 | 2017-07-27 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| CN107698684A (zh) * | 2016-08-03 | 2018-02-16 | 广东东阳光药业有限公司 | 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4628586A3 (en) | 2017-02-17 | 2026-01-14 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2019
- 2019-06-18 WO PCT/US2019/037695 patent/WO2019246071A1/en not_active Ceased
- 2019-06-18 US US17/253,391 patent/US20210284702A1/en not_active Abandoned
- 2019-06-18 KR KR1020217001552A patent/KR20210027377A/ko not_active Ceased
- 2019-06-18 BR BR112020025306-5A patent/BR112020025306A2/pt unknown
- 2019-06-18 EP EP19735097.8A patent/EP3807322A1/en active Pending
- 2019-06-18 PE PE2020002083A patent/PE20210323A1/es unknown
- 2019-06-18 CN CN201980039158.0A patent/CN112424233A/zh active Pending
- 2019-06-18 CA CA3101202A patent/CA3101202A1/en active Pending
- 2019-06-18 AU AU2019288212A patent/AU2019288212B2/en active Active
- 2019-06-18 MX MX2020012518A patent/MX2020012518A/es unknown
- 2019-06-18 TW TW108121124A patent/TWI874321B/zh active
- 2019-06-18 IL IL279510A patent/IL279510B2/en unknown
- 2019-06-18 JP JP2020570444A patent/JP7517997B2/ja active Active
- 2019-06-18 SG SG11202011743SA patent/SG11202011743SA/en unknown
-
2020
- 2020-12-11 PH PH12020552189A patent/PH12020552189A1/en unknown
- 2020-12-16 CL CL2020003255A patent/CL2020003255A1/es unknown
- 2020-12-16 EC ECSENADI202081591A patent/ECSP20081591A/es unknown
-
2023
- 2023-04-12 US US18/299,458 patent/US20230406898A1/en not_active Abandoned
-
2025
- 2025-02-04 US US19/044,856 patent/US20260001925A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022175A1 (en) * | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| US20170210808A1 (en) * | 2015-04-07 | 2017-07-27 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| WO2016207240A1 (en) * | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| CN107698684A (zh) * | 2016-08-03 | 2018-02-16 | 广东东阳光药业有限公司 | 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019246071A1 (en) | 2019-12-26 |
| PE20210323A1 (es) | 2021-02-18 |
| EP3807322A1 (en) | 2021-04-21 |
| BR112020025306A2 (pt) | 2021-03-09 |
| JP2021527656A (ja) | 2021-10-14 |
| CA3101202A1 (en) | 2019-12-26 |
| IL279510A (en) | 2021-01-31 |
| PH12020552189A1 (en) | 2021-06-28 |
| US20210284702A1 (en) | 2021-09-16 |
| AU2019288212B2 (en) | 2026-04-16 |
| ECSP20081591A (es) | 2021-01-29 |
| US20260001925A1 (en) | 2026-01-01 |
| AU2019288212A1 (en) | 2020-12-03 |
| TWI874321B (zh) | 2025-03-01 |
| KR20210027377A (ko) | 2021-03-10 |
| CL2020003255A1 (es) | 2021-05-28 |
| IL279510B2 (en) | 2025-11-01 |
| JP7517997B2 (ja) | 2024-07-17 |
| TW202016152A (zh) | 2020-05-01 |
| US20230406898A1 (en) | 2023-12-21 |
| IL279510B1 (en) | 2025-07-01 |
| SG11202011743SA (en) | 2021-01-28 |
| MX2020012518A (es) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260001925A1 (en) | Fusion proteins comprising progranulin | |
| US20230265137A1 (en) | Progranulin variants | |
| JP7854267B2 (ja) | 酵素補充療法用酵素を含む融合タンパク質 | |
| JP2020508049A (ja) | 操作されたトランスフェリン受容体結合ポリペプチド | |
| JP2020530293A (ja) | 操作されたトランスフェリン受容体結合ポリペプチド | |
| JP2020508053A (ja) | 操作されたポリペプチド | |
| HK40046687A (en) | Fusion proteins comprising progranulin | |
| EA049541B1 (ru) | Слитые белки, содержащие програнулин | |
| EA049817B1 (ru) | Варианты програнулина | |
| HK40079659A (en) | Progranulin variants | |
| HK40063309A (en) | Fusion proteins comprising enzyme replacement therapy enzymes | |
| HK40031685A (en) | Fusion proteins comprising enzyme replacement therapy enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40046687 Country of ref document: HK |